These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 1309380)

  • 21. [A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers].
    Takeuchi S; Dobashi K; Fujimoto S; Tanaka K; Suzuki M; Terashima Y; Hasumi K; Akiya K; Negishi Y; Tamaya T
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1681-9. PubMed ID: 1872624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.
    Perez-Soler R; Fossella FV; Glisson BS; Lee JS; Murphy WK; Shin DM; Kemp BL; Lee JJ; Kane J; Robinson RA; Lippman SM; Kurie JM; Huber MH; Raber MN; Hong WK
    J Clin Oncol; 1996 Feb; 14(2):503-13. PubMed ID: 8636764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study.
    Ueoka H; Tabata M; Kiura K; Shibayama T; Gemba K; Segawa Y; Chikamori K; Yonei T; Hiraki S; Harada M
    Br J Cancer; 1999 Feb; 79(5-6):984-90. PubMed ID: 10070901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose escalation study of paclitaxel in combination with fixed-dose irinotecan in patients with advanced non-small cell lung cancer (JCOG 9807).
    Yamada K; Ikehara M; Tanaka G; Nomura I; Oshita F; Noda K
    Oncology; 2004; 66(2):94-100. PubMed ID: 15138360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.
    Masuda N; Matsui K; Negoro S; Takifuji N; Takeda K; Yana T; Kobayashi M; Hirashima T; Kusunoki Y; Ushijima S; Kawase I; Tada T; Sawaguchi H; Fukuoka M
    J Clin Oncol; 1998 Oct; 16(10):3329-34. PubMed ID: 9779709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.
    DeVore RF; Johnson DH; Crawford J; Garst J; Dimery IW; Eckardt J; Eckhardt SG; Elfring GL; Schaaf LJ; Hanover CK; Miller LL
    J Clin Oncol; 1999 Sep; 17(9):2710-20. PubMed ID: 10561345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pilot study of irinotecan in refractory small cell lung cancer].
    Fujita A; Takabatake H; Tagaki S; Sekine K
    Gan To Kagaku Ryoho; 1995 Jun; 22(7):889-93. PubMed ID: 7793995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer.
    Kobayashi K; Shinbara A; Kamimura M; Takeda Y; Kudo K; Kabe J; Hibino S; Hino M; Shibuya M; Kudoh S
    Cancer Chemother Pharmacol; 1998; 42(1):53-8. PubMed ID: 9619758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
    Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
    Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group].
    Futatsuki K; Wakui A; Nakao I; Sakata Y; Kambe M; Shimada Y; Yoshino M; Taguchi T; Ogawa N
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):1033-8. PubMed ID: 8210254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer.
    Nogami N; Harita S; Ueoka H; Yonei T; Kiura K; Kamei H; Tabata M; Segawa Y; Gemba K; Tanimoto M
    Lung Cancer; 2004 Jul; 45(1):85-91. PubMed ID: 15196738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.
    Socinski MA; Sandler AB; Israel VK; Gillenwater HH; Miller LL; Locker PK; Antonellini A; Elfring GL; Natale RB
    Cancer; 2002 Oct; 95(7):1520-7. PubMed ID: 12237921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Phase I clinical study of CPT-11. Research group of CPT-11].
    Taguchi T; Wakui A; Hasegawa K; Niitani H; Furue H; Ohta K; Hattori T
    Gan To Kagaku Ryoho; 1990 Jan; 17(1):115-20. PubMed ID: 2404454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Limited sampling model for the area under the concentration versus time curve of irinotecan and its application to a multicentric phase II trial.
    Yamamoto N; Tamura T; Nishiwaki Y; Kurita Y; Kawakami Y; Abe S; Nakabayashi T; Suzuki S; Matsuda T; Hayashi I; Takahashi T; Saijo N
    Clin Cancer Res; 1997 Jul; 3(7):1087-92. PubMed ID: 9815787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer.
    Morise M; Niho S; Umemura S; Matsumoto S; Yoh K; Goto K; Ohmatsu H; Ohe Y
    Jpn J Clin Oncol; 2014 Sep; 44(9):846-51. PubMed ID: 25057092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.
    Socinski MA; Sandler AB; Miller LL; Locker PK; Hanover CK; Elfring GL; Israel VK; Pirotta N; Natale RB
    J Clin Oncol; 2001 Feb; 19(4):1078-87. PubMed ID: 11181672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer.
    Takeda K; Takifuji N; Uejima H; Yoshimura N; Terakawa K; Negoro S
    Lung Cancer; 2002 Dec; 38(3):303-8. PubMed ID: 12445753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with advanced breast cancer].
    Taguchi T; Yoshida Y; Izuo M; Ishida T; Ogawa M; Nakao I; Tominaga T; Ohkawa T; Oguro M; Yoshida M
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):83-90. PubMed ID: 8291919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer.
    Sugiura T; Ariyoshi Y; Negoro S; Nakamura S; Ikegami H; Takada M; Yana T; Fukuoka M
    Invest New Drugs; 2005 Aug; 23(4):331-7. PubMed ID: 16012792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion.
    Ohe Y; Sasaki Y; Shinkai T; Eguchi K; Tamura T; Kojima A; Kunikane H; Okamoto H; Karato A; Ohmatsu H
    J Natl Cancer Inst; 1992 Jun; 84(12):972-4. PubMed ID: 1321253
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.